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Abstract
Well-differentiated papillary mesothelioma is an uncommon mesothelial neoplasm that most 
frequently arises in the peritoneal cavity of women of reproductive age. Whereas malignant 
mesothelioma is an aggressive tumor associated with poor outcome, well-differentiated papillary 
mesothelioma typically exhibits indolent behavior. However, histologically differentiating between 
these two entities can be challenging, necessitating the development of distinguishing biomarkers. 
While the genetic alterations that drive malignant mesothelioma have recently been determined, 
the molecular pathogenesis of well-differentiated papillary mesothelioma is unknown. Here we 
performed genomic profiling on a cohort of ten well-differentiated papillary mesothelioma of the 
peritoneum. We identified that all tumors harbored somatic missense mutations in either the 
TRAF7 or CDC42 genes, and lacked alterations involving BAP1, NF2, CDKN2A, DDX3X, 
SETD2, and ALK that are frequent in malignant mesothelioma. We recently identified that another 
mesothelial neoplasm, adenomatoid tumor of the genital tract, is genetically defined by somatic 
missense mutations in the TRAF7 gene, indicating a shared molecular pathogenesis between well-
differentiated papillary mesothelioma and adenomatoid tumors. To the best of our knowledge, 
well-differentiated papillary mesothelioma is the first human tumor type found to harbor recurrent 
mutations in the CDC42 gene, which encodes a Rho family GTPase. Immunohistochemistry 
demonstrated intact BAP1 expression in all cases of well-differentiated papillary mesothelioma, 
indicating that this is a reliable marker for distinguishing well-differentiated papillary 
mesothelioma from malignant mesotheliomas that frequently display loss of expression. 
Additionally, all well-differentiated papillary mesothelioma demonstrated robust expression of L1 
cell adhesion molecule (L1CAM), a marker of NF-kB pathway activation, similar to that observed 
in adenomatoid tumors. In contrast, we have previously shown that L1CAM staining is not 
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observed in normal mesothelial cells and malignant mesotheliomas of the peritoneum. Together, 
these studies demonstrate that well-differentiated papillary mesothelioma is genetically defined by 
mutually exclusive mutations in TRAF7 and CDC42 that molecularly distinguish this entity from 
malignant mesothelioma.
Keywords
well-differentiated papillary mesothelioma (WDPM); adenomatoid tumor; malignant 
mesothelioma; mesothelial cells; TRAF7; tumor necrosis factor alpha (TNFα); nuclear factor-
kappa B (NF-kB); L1CAM; CDC42; Rho family GTPase
INTRODUCTION
Well-differentiated papillary mesothelioma (commonly abbreviated WDPM) is a relatively 
uncommon subtype of mesothelial neoplasm that is most frequently found in women of 
reproductive age, but can also be seen in men and post-menopausal women.1–7 Unlike 
malignant mesothelioma, well-differentiated papillary mesothelioma is not associated with 
prior asbestos exposure. Well-differentiated papillary mesothelioma most commonly arises 
in the peritoneal cavity, but can also be found in the pleural cavity, pericardium, and tunica 
vaginalis.8,9 These tumors are usually discovered incidentally during surgical procedures for 
other clinical indications, often in close proximity to the associated principal pathology. 
Histologically, well-differentiated papillary mesothelioma are an exophytic papillary 
neoplasm lined by a single layer of cuboidal mesothelial cells with bland nuclear cytology 
and very low to absent mitotic activity. Typically, they are solitary lesions that lack 
architectural complexity and stromal invasion. Well-differentiated papillary mesothelioma 
express markers typical of mesothelial cells including calretinin, WT1, D2–40, and 
cytokeratin 5/6. Well-differentiated papillary mesothelioma typically follow an indolent or 
benign clinical course, in contrast to malignant mesothelioma that is a highly aggressive 
tumor associated with poor outcome. However, there are several reported cases of well-
differentiated papillary mesothelioma behaving in a malignant fashion, with dissemination 
leading to patient mortality.4,7,10 Whether such cases represent malignant transformation of 
well-differentiated papillary mesothelioma or instead represent misclassified malignant 
mesotheliomas is unknown. These tumor entities can often be reliably differentiated in 
resection specimens based on the presence of nuclear atypia, mitotic activity, and complex 
architecture in malignant mesotheliomas that are not found in well-differentiated papillary 
mesothelioma.11–13 However, differentiating between these two entities in small biopsy or 
cytology specimens can be challenging given their shared mesothelial cell of origin and lack 
of distinguishing biomarkers. Therefore, it is critical to identify such biomarkers that help to 
differentiate well-differentiated papillary mesothelioma from malignant mesothelioma and 
better predict outcome for patients with mesothelial neoplasms.
There is currently controversy in the literature regarding the true biologic nature of well-
differentiated papillary mesothelioma, and no defining molecular alterations have been 
identified to date to prove that these are indeed clonal neoplasms. Some authors have 
hypothesized that well-differentiated papillary mesothelioma represents reactive mesothelial 
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hyperplasia, given that these lesions are often found adjacent to another principal pathology 
or in patients with a prior history of surgery.14 Other authors consider well-differentiated 
papillary mesothelioma to be a neoplasm of uncertain malignant potential and have treated 
patients with adjuvant chemotherapy upon diagnosis.2,7 Here we performed genomic 
analysis on a cohort of ten well-differentiated papillary mesothelioma of the peritoneum in 
order to assess the molecular pathogenesis of this poorly understood mesothelial neoplasm.
MATERIALS AND METHODS
Study population and tumor specimens
This study was approved by the Institutional Review Board of the University of California, 
San Francisco. Ten cases of well-differentiated papillary mesothelioma of the peritoneum 
were retrieved from the pathology archives of our institution, spanning years 1993 to 2014. 
All tumor specimens had been fixed in 10% neutral-buffered formalin and embedded in 
paraffin. Paraffin embedded blocks of uninvolved normal tissue (e.g. lymph node or 
gastrointestinal biopsy) were also retrieved for nine of the ten patients. Pathologic review of 
all tumor samples was performed to confirm the diagnosis by a group of expert gynecologic 
pathologists (J.T.R., K.G., C.Z., and D.A.S.).
Targeted next-generation DNA sequencing and mutational analysis
Tumor tissue and uninvolved normal tissue was macrodissected from formalin-fixed, 
paraffin-embedded blocks for the 10 patients. Genomic DNA was extracted from the 
macrodissected tissue using the QIAamp DNA FFPE Tissue Kit (Qiagen) according to the 
manufacturer’s protocol. Capture-based next-generation DNA sequencing was performed at 
the UCSF Clinical Cancer Genomics Laboratory as previously described using an assay that 
targets all coding exons of 479 cancer-related genes, TERT promoter, select introns and 
upstream regulatory regions of 47 genes to enable detection of structural variants including 
gene fusions, and DNA segments at regular intervals along each chromosome to enable 
genome-wide copy number and zygosity analysis, with a total sequencing footprint of 2.8 
Mb (UCSF500 Cancer Panel; Supplementary Table 1).15,16 Sequencing libraries were 
prepared from genomic DNA, and target enrichment was performed by hybrid capture using 
a custom oligonucleotide library (Roche NimbleGen). Sequencing was performed on an 
Illumina HiSeq 2500. Duplicate sequencing reads were removed computationally to allow 
for accurate allele frequency determination and copy number calling. The analysis was 
based on the human reference sequence (NCBI build 37) using the following software 
packages: BWA, Samtools, Picard tools, GATK, CNVkit, Pindel, SATK, Annovar, 
Freebayes, and Delly. Single nucleotide variants, insertions/deletions, and structural variants 
were visualized and verified using the Integrated Genome Viewer. Genome-wide copy 
number analysis based on on-target and off-target reads was performed by CNVkit and 
Nexus Copy Number (Biodiscovery).
Immunohistochemistry for BAP1 and L1CAM
Immunohistochemistry was performed on whole formalin-fixed, paraffin-embedded tissue 
sections of nine of the ten cases of well-differentiated papillary mesothelioma. 
Immunohistochemistry for BAP1 was performed using a mouse monoclonal anti-BAP1 
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antibody (clone C-4, Santa Cruz Biotechnology, sc-28383) at 1:100 dilution following ER2 
antigen retrieval in a Leica Bond automated stainer. Immunohistochemistry for L1CAM was 
performed using a mouse monoclonal anti-L1CAM antibody (clone UJ127.11, Sigma, 
L4543) at 1:1,800 dilution following antigen retrieval in a Ventana Benchmark automated 
stainer. Diaminobenzidine was used as the chromogen, followed by hematoxylin 
counterstain. BAP1 staining was scored as either intact (strong homogeneous nuclear 
staining of >90% of tumor cells) or lost (no nuclear staining in tumor cells with intact 
expression in non-neoplastic stromal and endothelial cells). No cases showed a mosaic 
staining pattern for BAP1. L1CAM staining was scored as either positive (membranous 
staining on a majority of tumor cells) or negative (absence of staining). No cases showed 
L1CAM staining in only a minority of the tumor cells. The BAP1 immunohistochemical 
staining results shown in Figure 6 for normal mesothelial cells, adenomatoid tumor of the 
genital tract, and malignant peritoneal mesothelioma were previously reported by Joseph et 
al.15 The L1CAM immunohistochemical staining results shown in Figure 6 for normal 
mesothelial cells, adenomatoid tumor of the genital tract, and malignant peritoneal 
mesothelioma were previously reported by Goode et al.16
RESULTS
Clinical features of the well-differentiated papillary mesothelioma patient cohort
In order to study the molecular pathogenesis of well-differentiated papillary mesothelioma, 
we assembled a cohort of tumor and matched normal tissue from ten patients for genomic 
analysis. The clinical features of this patient cohort are listed in Table 1. The three male and 
seven female patients ranged in age from 54–84 years (median 66 years). All of the tumors 
were located in the peritoneum and were incidentally found during surgical procedures for 
other clinical indications including Nissen fundoplication for gastroesophageal reflux 
disease, rectal prolapse repair, prophylactic salpingo-oophorectomy, and gastrectomy for 
adenocarcinoma of the stomach. In all cases, the tumors were identified in the immediate 
vicinity of the principal pathology being surgically repaired or excised. For example, tumors 
were located on the gastric surface or gastrohepatic ligament of patients undergoing Nissen 
fundoplication or were on the serosal surface of the neobladder in a patient with a history of 
cystectomy for invasive urothelial carcinoma. Eight of the patients harbored solitary tumors 
ranging in size from 2 to 12 mm. One of the patients (WDPM #1) harbored two distinct 
tumor nodules both approximately 5 mm that were found in close proximity on the 
gastrohepatic ligament during gastrectomy for signet ring cell adenocarcinoma. Another 
patient (WDPM #8) harbored several tumor nodules ranging from 2 to 10 mm that were 
found in close proximity along the posterior pelvic wall during risk-reducing salpingo-
oophorectomy. None of patients received any adjuvant therapy directed at the well-
differentiated papillary mesothelioma beyond surgical excision, but three of the patients did 
receive systemic chemotherapy for other indications. None of the patients in this cohort 
experienced disease recurrence after a median clinical follow-up of 3.1 years, which 
included three patients who underwent subsequent abdominal exploration after tumor 
excision.
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Histologic features of the well-differentiated papillary mesothelioma cohort
Histologic features of the ten tumors are shown in Supplementary Figure 1. All cases 
consisted of an exophytic papillary proliferation of mesothelial cells with central 
fibrovascular cores containing a variable amount of collagenous and edematous stroma. The 
papillary cores were lined by a single layer of cuboidal mesothelial cells and uniformly 
lacked nuclear atypia and any appreciable mitotic activity. In three cases, 
immunohistochemical stains for calretinin, WT1, and cytokeratin 5/6 had been performed as 
part of the diagnostic workup and were all positive in the tumor cells, supporting the 
diagnosis of a mesothelial neoplasm (data not shown).
Genomic analysis of well-differentiated papillary mesothelioma
Targeted next-generation sequencing was performed on genomic DNA isolated from the ten 
tumors and matched normal tissue as described in the Methods. This identified somatic 
missense mutations in the TRAF7 gene or CDC42 gene in all ten cases (Figures 1–2, 
Supplementary Table 2). Mutations in TRAF7 and CDC42 were mutually exclusive, with 
seven cases that harbored TRAF7 mutations and were CDC42 wildtype, while the remaining 
three cases harbored CDC42 mutations and were TRAF7 wildtype (Figure 3). These TRAF7 
and CDC42 missense mutations were verified to be somatic (i.e. tumor-specific) in all cases 
with available matched normal tissue (n=9). Snapshots of the TRAF7 and CDC42 mutations 
are shown in Supplementary Figure 2.
TRAF7 encodes an E3 ubiquitin ligase and is a member of the family of tumor necrosis 
factor alpha receptor-associated factors (TRAFs). Somatic mutations in the TRAF7 gene 
have been recently identified as a defining genetic feature of adenomatoid tumors of the 
genital tract,16 and are also frequent in perineuriomas and meningiomas.17–19 Similar to the 
TRAF7 mutations observed in these tumor types, the TRAF7 mutations in well-
differentiated papillary mesothelioma were all missense mutations that clustered in the 
WD40 repeats at the C-terminus of the protein (Figure 4). In five of the seven cases 
harboring TRAF7 mutations, a single missense mutation was present. WDPM #3 harbored a 
focal amplification of the TRAF7 gene on chromosome 16p13 and two TRAF7 missense 
mutations (p.N520D and p.G536S) that were either present in trans (on opposite alleles) or 
within separate tumor subclones. WDPM #4 harbored three TRAF7 missense mutations 
(p.G536S, p.Q539H, and p.Y621D; Supplementary Figure 2). The p.G536S and p.Q539H 
mutations were present either in trans or within separate subclones, while the p.Y621D 
mutation was too distant to phase. In addition to the recurrent TRAF7 mutations found in 
well-differentiated papillary mesothelioma, the presence of a focal amplification in one case 
and multiple mutations in two cases indicates a strong selection pressure for the acquisition 
of TRAF7 alterations during the development of well-differentiated papillary mesothelioma. 
The variant allele frequencies for the TRAF7 mutations ranged from 4–45%. Cases with the 
highest TRAF7 variant allele frequencies had genomic DNA isolated from areas 
histologically visualized to contain a high tumor cell content, whereas cases with lower 
allele frequencies had genomic DNA that was isolated from tissue visualized to contain a 
lesser tumor to normal cell content. These data suggest that TRAF7 mutations were likely 
heterozygous and clonal (i.e. present in all tumor cells), indicating that they are probably an 
early or initiating event in well-differentiated papillary mesothelioma tumorigenesis.
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CDC42 encodes a Rho family GTPase belonging to the Ras superfamily of GTPases. Two 
well-differentiated papillary mesothelioma cases harbored the identical p.Q61R mutation in 
CDC42, while a third case harbored p.P34Q mutation. Similar to the TRAF7 mutations, the 
variant allele frequencies for the CDC42 mutations (ranging from 20–38%) indicated that 
these are also likely to be clonal heterozygous alterations in well-differentiated papillary 
mesothelioma and are probably early or initiating genetic events in those well-differentiated 
papillary mesothelioma lacking TRAF7 alterations. The p.Q61R mutation is located within a 
GTP binding domain, whereas the p.P34Q mutation is located within the effector domain 
(Figure 5a). Amino acid sequence of CDC42 was aligned with the related Rho family 
GTPases RAC1 and RHOA, as well as the homologous Ras family GTPases (NRAS, HRAS, 
and KRAS), which are all known to be recurrently mutated in human cancers (Figure 5b). 
Mutational hotspots in each of these proteins was annotated using data from the Catalogue 
of Somatic Mutations in Cancer (COSMIC) database [version 84 release]. Recurrent 
mutations in the CDC42 gene have not been previously reported in any human tumor type to 
the best of our knowledge, and the p.Q61R and p.P34Q variants in CDC42 are not present in 
the COSMIC database. However, the p.Q61 residue of CDC42 located in the highly 
conserved GTP binding domain is the equivalent residue to p.Q61 in the NRAS, HRAS, and 
KRAS proteins, which is a mutational hotspot with thousands of confirmed somatic 
mutations in human cancers present in the COSMIC database. The p.P34 residue in the 
effector domain of CDC42 where a mutation was identified in WDPM #10 does not 
correspond to a mutational hotspot in any of the other Rho or Ras family GTPases.
In the two patients with multiple distinct tumor nodules (WDPM #1 and 8), genomic DNA 
was pooled from the multiple nodules to ensure adequate sequencing depth. In both of these 
tumors, only a single TRAF7 mutation or CDC42 mutation was identified, respectively. This 
indicates that the multiple tumor nodules that were found in close proximity were likely to 
share a common ancestral clone, rather than representing multiple distinct tumors. 
Additionally, the TRAF7 and CDC42 mutations were the solitary somatic alterations 
identified in these two cases, indicating that these well-differentiated papillary mesothelioma 
did not acquire accompanying genetic alterations among the assayed genes to explain the 
multifocal growth.
Beyond TRAF7 and CDC42, none of the other 477 sequenced genes contained recurrent 
somatic mutations in the ten well-differentiated papillary mesothelioma. While five cases 
contained additional somatic nonsynonymous mutations in addition to TRAF7 or CDC42, 
all of these additional mutations are considered variants of unknown significance, as they do 
not affect genes known to be important in mesothelioma tumorigenesis and are not 
mutations that have been previously seen before in human cancers (COSMIC database, 
version 84 release). The complete list of somatic single nucleotide variants and insertions/
deletions identified in the well-differentiated papillary mesothelioma cohort is shown in 
Supplementary Table 2. The total somatic mutation burden was low in all tumors (uniformly 
less than 2 somatic mutations per megabase). Chromosomal copy number analysis revealed 
trisomy 7 and focal amplification of chromosome 16p13.3 containing the TRAF7 gene in 
WDPM #3 (Supplementary Table 3). None of the other nine cases harbored chromosomal 
gains, losses, or focal amplifications or deletions. All tumors lacked identifiable mutations, 
deletions, or rearrangements involving the BAP1, CDKN2A, NF2, DDX3X, SETD2, TP53, 
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and ALK genes known to be recurrently altered in pleural or peritoneal malignant 
mesotheliomas.15,20–23
BAP1 and L1CAM immunohistochemical assessment of well-differentiated papillary 
mesothelioma
The BAP1 tumor suppressor gene has emerged as a frequent target of inactivating mutations, 
deletions, or rearrangements in malignant mesothelioma, particularly in peritoneal cases 
where genetic alterations and associated loss of nuclear BAP1 immunostaining are seen in 
greater than 80% of cases according to multiple case series.15,24–29 In contrast, we have 
previously documented intact BAP1 expression by immunohistochemistry in normal 
mesothelial cells of the peritoneum, adenomatoid tumors of the genital tract (n=16), and 
well-differentiated papillary mesothelioma of the peritoneum (n=6).15 Here we find intact 
BAP1 expression in all nine of the well-differentiated papillary mesothelioma cases in this 
cohort with tissue available for immunohistochemical evaluation (Figure 6).
TRAF7 belongs to the family of TNFα receptor-associated factors that are known to 
regulate the nuclear factor-kappa B (NF-kB) signaling pathway.30 We previously 
demonstrated that tumor-derived TRAF7 mutations induce activation of NF-kB signaling 
and cause increased expression of L1 cell adhesion molecule (L1CAM),16 a known 
transcriptional target of NF-kB that has emerged as a reliable surrogate marker for tumors 
with activated NF-kB signaling.31,32 Here we find strong membranous staining for L1CAM 
protein in all nine of the well-differentiated papillary mesothelioma cases in this cohort with 
tissue available for immunohistochemical evaluation (Figure 6), which include both TRAF7 
and CDC42 mutant cases. This was comparable to the L1CAM expression we previously 
documented in adenomatoid tumors of the genital tract harboring TRAF7 mutations (n=8), 
whereas no appreciable L1CAM staining was seen in normal mesothelial cells lining organs 
of the peritoneal cavity (n=7), nor was staining seen in malignant peritoneal mesotheliomas 
(n=7) or multilocular peritoneal inclusion cysts (n=6).16 Similar to adenomatoid tumors of 
the genital tract, these data suggest that well-differentiated papillary mesothelioma are also 
characterized by activated NF-kB signaling, which in well-differentiated papillary 
mesothelioma can be due to either TRAF7 or CDC42 mutation.
DISCUSSION
Our study identifies mutually exclusive somatic mutations of TRAF7 and CDC42 in all 
cases of well-differentiated papillary mesothelioma of the peritoneum. These results confirm 
that well-differentiated papillary mesothelioma is indeed a clonal neoplasm, and refute the 
hypothesis that this lesion represents reactive mesothelial hyperplasia.14 Beyond TRAF7 or 
CDC42 mutation, all tumors had relatively simple genomes with few, if any, additional 
somatic mutations or chromosomal copy number alterations. The presence of a solitary 
pathogenic alteration in either TRAF7 or CDC42 in all cases of well-differentiated papillary 
mesothelioma is in keeping with the low grade nature of these neoplasms.
We recently identified that adenomatoid tumors of the genital tract are genetically defined by 
somatic missense mutations in the TRAF7 gene that similarly localize in the WD40 repeats 
at the C-terminus of the protein.16 Thus, in addition to sharing a mesothelial cell of origin, 
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both well-differentiated papillary mesothelioma of the peritoneum and adenomatoid tumors 
of the genital tract share a common molecular pathogenesis. We thus speculate that well-
differentiated papillary mesothelioma of the peritoneum and adenomatoid tumors of the 
genital tract may be a single entity that harbors different names depending on the site of 
origin. In support of this hypothesis are several reported cases of tumors showing mixed 
features of well-differentiated papillary mesothelioma and adenomatoid tumor.6,33 
Transcriptional or epigenetic profiling of these two tumors is likely to be helpful in 
clarifying this hypothesis, which may reveal a similar transcriptional and epigenetic 
landscape if indeed they represent a single entity. Of note though is that a subset of well-
differentiated papillary mesothelioma lack TRAF7 mutations and instead harbor CDC42 
mutations, whereas all 31 of the adenomatoid tumors of the genital tract harbored TRAF7 
mutations and lacked CDC42 mutations in our initial study.16
The well-differentiated papillary mesothelioma of the peritoneum in this cohort all had intact 
BAP1 expression and lacked alterations in the BAP1, NF2, CDKN2A, DDX3X, SETD2, 
TP53, and ALK genes that are commonly altered in malignant mesotheliomas of the pleural 
and peritoneal cavities.15,20–23 Thus, well-differentiated papillary mesothelioma appears to 
be genetically distinct from malignant mesothelioma. However, while TRAF7 mutations 
have not been reported in any cases of malignant peritoneal mesothelioma, they were 
reportedly seen in a small number of malignant pleural mesotheliomas in one recent study (5 
of 216 cases, 2%).22 Two of the five TRAF7-mutant tumors harbored additional BAP1 and 
TP53 mutations, one harbored additional NF2 mutation, and two lacked additional 
pathogenic alterations.22 Whether these cases represent misclassified well-differentiated 
papillary mesothelioma of the pleural cavity is one possibility, which would be supported by 
the presence of solitary TRAF7 mutations. Another consideration is that these cases 
represent well-differentiated papillary mesothelioma that underwent malignant 
transformation, which would be supported by the presence of TRAF7 mutation combined 
with other pathogenic alterations such as BAP1 or NF2. Or a third explanation is that 
TRAF7 mutation can be selected for during tumor development in a small subset of de novo 
malignant mesotheliomas without progression from a well-differentiated papillary 
mesothelioma-like precursor. Further investigation of patients with malignant mesotheliomas 
harboring TRAF7 mutation is required to understand the biologic nature of these tumors.
In addition to well-differentiated papillary mesothelioma and adenomatoid tumors of the 
genital tract, TRAF7 mutations are also common in meningiomas and perineuriomas. 
However, the mechanisms by which TRAF7 mutations contribute to tumor development are 
not well described. The TRAF7 gene encodes an E3 ubiquitin ligase within the family of 
TNF-alpha receptor-associated factor (TRAF) proteins and is thought to regulate the NF-kB 
signaling pathway. We have previously shown that expression of tumor-derived mutant 
isoforms but not wildtype TRAF7 in cultured human cells causes increased phosphorylation 
of the p65/RELA subunit of NF-kB, a modification associated with activation, and also 
upregulation of L1CAM expression, a downstream transcriptional target of NF-kB.16 
Similar to the robust expression of L1CAM seen in adenomatoid tumors harboring TRAF7 
mutations, here we show that well-differentiated papillary mesothelioma are also 
characterized by robust L1CAM expression, indicative of active NF-kB signaling. Robust 
L1CAM expression was observed in both TRAF7 and CDC42 mutant well-differentiated 
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papillary mesothelioma, indicating that CDC42 mutations may potentially be an alternative 
mechanism of driving NF-kB signaling in TRAF7 wildtype mesothelial neoplasms.
CDC42 encodes a small GTPase of the Rho family of proteins belonging to the Ras 
superfamily of GTPases. CDC42 was first discovered in budding yeast as a temperature 
sensitive mutant that was defective in budding, while still maintaining the ability to replicate 
its DNA.34 CDC42 is now known to be critical for determination of cell polarity and 
regulation of the actin cytoskeleton including filopodia formation at leading edge during cell 
motility.35 Studies have also shown that Rho family GTPases including CDC42 regulate NF-
kB signaling and cell cycle progression.36,37 We are currently investigating which of these 
functions of CDC42 are abrogated by mutations to drive well-differentiated papillary 
mesothelioma tumorigenesis. Given the presence of heterozygous missense mutations that 
localize within the GTP binding and effector domains, we anticipate that these are likely to 
be oncogenic, gain-of-function mutations, as opposed to tumor suppressive, loss-of-function 
variants. While other Rho family GTPases are known to be recurrently mutated in cancer 
(e.g. RAC1 in melanoma and RHOA in gastric adenocarcinoma and angioimmunoblastic T 
cell lymphoma38–42), CDC42 has not been identified as a recurrently mutated gene in any 
human tumor type to date apart from well-differentiated papillary mesothelioma to the best 
of our knowledge. Why CDC42 mutations are selected for during mesothelioma 
development, but not any of the other Ras family GTPases is an interesting question that 
remains to be answered.
In summary, we have characterized the genetic landscape of well-differentiated papillary 
mesothelioma of the peritoneum that revealed mutually exclusive mutations in TRAF7 and 
CDC42, along with an absence of genetic alterations that are common in malignant 
mesothelioma such as BAP1, NF2, CDKN2A, DDX3X, SETD2, TP53, and ALK. 
Furthermore, we show that the combination of BAP1 and L1CAM immunohistochemistry is 
likely to be a reliable methodology for differentiating well-differentiated papillary 
mesothelioma from malignant mesothelioma in the majority of cases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Well-differentiated papillary mesothelioma of the peritoneum harbors frequent somatic 
mutations of the TRAF7 gene. (a, b) Hematoxylin and eosin stained sections of WDPM #2 
excised from the gastric surface of a 66 year old woman after incidental discovery during 
Nissen fundoplication for gastroesophageal reflux. (c) Next-generation sequencing reads 
from the tumor and uninvolved normal gastric tissue demonstrating a somatic TRAF7 
p.N520S missense mutation (c.1559A>G).
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Figure 2. 
Well-differentiated papillary mesothelioma of the peritoneum harbors somatic CDC42 
mutations in those cases lacking TRAF7 alterations. (a, b) Hematoxylin and eosin stained 
sections of WDPM #10 excised from the gastric surface of an 84 year old woman after 
incidental discovery during Nissen fundoplication for gastroesophageal reflux. (c) Next-
generation sequencing reads from the tumor and uninvolved normal gastric tissue 
demonstrating a somatic CDC42 p.P34Q missense mutation (c.101C>A).
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Figure 3. 
Oncoprint summary table of the 10 patients with well-differentiated papillary mesothelioma 
of the peritoneum. Patient age, sex, number of tumor nodules, TRAF7 and CDC42 mutation 
status, number of additional somatic mutations, quantity of chromosomal copy number 
alterations, and immunohistochemical staining results for L1CAM and BAP1 are shown.
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Figure 4. 
Diagram of the human TRAF7 protein with locations of the somatic missense mutations 
identified in the 10 cases of well-differentiated papillary mesothelioma. Also shown are 
locations of the missense mutations in the 31 adenomatoid tumors of the genital tract 
recently reported by Goode et al.16 The mutations all cluster within the WD40 repeats at the 
C-terminus of the protein.
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Figure 5. 
(a) Diagram of the human CDC42 protein with locations of the somatic missense mutations 
identified in the 10 cases of well-differentiated papillary mesothelioma. The mutations are 
present within GTP binding and effector domains of the protein. (b) Amino acid sequence 
from the N-terminus of CDC42, the related Rho family GTPases RAC1 and RHOA, and the 
homologous Ras family GTPases. Residues that are recurrently mutated in human cancers 
are highlighted in blue, including the p.Q61 mutational hotspot in NRAS, HRAS, and 
KRAS. The residues in CDC42 found to harbor somatic mutations in well-differentiated 
papillary mesothelioma are highlighted in yellow. These include the p.Q61 residue (mutated 
in two cases) located in the highly conserved GTP binding domain that is the equivalent 
residue to the p.Q61 mutational hotspot in the Ras family proteins. The p.P34 residue 
(mutated in one case) located in the effector domain does not correspond to a mutational 
hotspot in any of other Rho or Ras family GTPases.
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Figure 6. 
Immunohistochemistry for BAP1 and L1 cell adhesion molecule (L1CAM) on mesothelial 
neoplasms of the peritoneum. BAP1 staining shows intact/retained expression in all cases of 
well-differentiated papillary mesothelioma of the peritoneum and adenomatoid tumors of the 
genital tract, with frequent somatic loss of expression in malignant peritoneal mesothelioma. 
L1CAM staining shows robust staining with the expected membranous pattern in all 
examined cases of well-differentiated papillary mesothelioma and adenomatoid tumors of 
the genital tract, whereas L1CAM expression is absent in normal mesothelial cells and 
malignant peritoneal mesotheliomas.
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